Login
$VIR
$9.62 +$0.04 (0.42%) After hours

Company Executives

Officer Age 2025 pay Source
Marianne De Backer Also a director
President and CEO
Title from the Form 4 dated Apr 29, 2026
57 $7,834,045
Aziz Sawaf
EVP, Chief Financial Officer
Title from the Form 4 dated Nov 15, 2026
Not stated Not reported
Mark Eisner
Executive Vice President and Chief Medical Officer
60 $2,371,484
Vanina de Verneuil
EVP, General Counsel, Corp Sec
Title from the Form 4 dated Nov 2, 2026
47 $1,690,784
Brent Sabatini
SVP, Chief Accounting Officer
Title from the Form 4 dated Nov 15, 2026
Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 16, 2026 · updated by the 8-Ks of May 28, 2026, Jun 10, 2026, and Oct 28, 2026

Directors
10
serving now
Independent
6 of 6
stated in the proxy; 4 not stated
Average tenure
5.0 years
from year joined
CEO also chairs the board
No
Jeffrey S. Hatfield and Vicki Sato
Director Age On board Independent Committees Other public boards 2025 pay Source
Jeffrey S. Hatfield
68 2020
6 years
Independent
Audit Nominating and Corporate Governance · Chair
None stated $184,645
Marianne De Backer
57 2023
3 years
Not stated None stated None stated Paid as CEO
Norbert Bischofberger
70 2024
2 years
Independent
Compensation Science and Technology
None stated Not stated
Ramy Farid
61 2024
2 years
Independent
Audit Science and Technology
Schrödinger, Inc. Not stated
Robert More
58 2016
10 years
Independent
Audit · Chair Compensation · Chair
Tyra Biosciences, Inc. (Chairman) (2021 – present) $182,860
Janet Napolitano
68 2020
6 years
Independent
Compensation Nominating and Corporate Governance
Fortinet, Inc. (2024 – present) $159,975
Elliott Sigal
74 2020
6 years
Independent
Compensation Science and Technology · Chair
Alnylam Pharmaceuticals, Inc. (2022 – present) Not stated
Timothy Coughlin Joined Jun 10, 2026
- - -
Audit Committee · Chair
- -
Suzanne Topalian Joined Oct 27, 2026
- - -
Science and Technology Committee
- -
Vicki Sato Leaving at the meeting
Not stated Not stated Not stated None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

2 disclosed in the proxy filed Apr 16, 2026
GSK
Amount not stated
2023

Amendments No. 2 and No. 3 to the 2020 GSK collaboration agreement, removing the CoV Vaccine Program and modifying the coronavirus antibody program, with tiered royalties payable to GSK.

With Glaxo Wellcome UK Limited (GW) and GlaxoSmithKline Biologicals S.A. (GSK Bio) Open in proxy
GSK
Amount not stated
2024

Letter Agreement terminating the collaboration on the Influenza Program under the Definitive Collaboration Agreement, with royalty payments to GW on certain influenza products.

With Glaxo Wellcome UK Limited (GW) Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support